These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 15631012)

  • 1. Report on the mid-term assessment of microfilaraemia reduction in sentinel sites of 13 countries of the Global Programme to Eliminate Lymphatic Filariasis.
    Wkly Epidemiol Rec; 2004 Oct; 79(40):358-65. PubMed ID: 15631012
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of albendazole in programmes to eliminate lymphatic filariasis.
    Ottesen EA; Ismail MM; Horton J
    Parasitol Today; 1999 Sep; 15(9):382-6. PubMed ID: 10461168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global programme to eliminate lymphatic filariasis.
    World Health Organization
    Wkly Epidemiol Rec; 2005 Jun; 80(23):202-12. PubMed ID: 16033148
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.
    Fischer PU; King CL; Jacobson JA; Weil GJ
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005163. PubMed ID: 28056015
    [No Abstract]   [Full Text] [Related]  

  • 5. Improving community participation to eliminate lymphatic filariasis in American Samoa.
    King JD; Zielinski-Gutierrez E; Pa'au M; Lammie P
    Acta Trop; 2011 Sep; 120 Suppl 1():S48-54. PubMed ID: 20932818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphatic filariasis elimination programme in India: progress and challenges.
    Ramaiah KD
    Trends Parasitol; 2009 Jan; 25(1):7-8. PubMed ID: 19008150
    [No Abstract]   [Full Text] [Related]  

  • 7. Evidence for the use of albendazole for the elimination of lymphatic filariasis.
    Sunish IP; Rajendran R; Mani TR; Dash AP; Tyagi BK
    Lancet Infect Dis; 2006 Mar; 6(3):125-6. PubMed ID: 16500593
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of the program to eliminate lymphatic filariasis in Vanuatu following two years of mass drug administration implementation: results and methodologic approach.
    Fraser M; Taleo G; Taleo F; Yaviong J; Amos M; Babu M; Kalkoa M
    Am J Trop Med Hyg; 2005 Oct; 73(4):753-8. PubMed ID: 16222021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
    de Kraker ME; Stolk WA; van Oortmarssen GJ; Habbema JD
    Trop Med Int Health; 2006 May; 11(5):718-28. PubMed ID: 16640625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Filariasis elimination, Zanzibar.
    Wkly Epidemiol Rec; 2001 Dec; 76(51-52):406-8. PubMed ID: 11789061
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of single dose of diethylcarbamazine and other antifilarial drug combinations on bancroftian filarial infection variables: assessment after 2 years.
    Sunish IP; Rajendran R; Mani TR; Munirathinam A; Reuben R; Dash AP
    Parasitol Int; 2006 Sep; 55(3):233-6. PubMed ID: 16807079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endpoints for lymphatic filariasis programs.
    Grady CA; de Rochars MB; Direny AN; Orelus JN; Wendt J; Radday J; Mathieu E; Roberts JM; Streit TG; Addiss DG; Lammie PJ
    Emerg Infect Dis; 2007 Apr; 13(4):608-10. PubMed ID: 17553278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Report on active surveillance for adverse events following the use of drug co-administrations in the global programme to eliminate lymphatic filariasis.
    Wkly Epidemiol Rec; 2003 Sep; 78(36):315-7. PubMed ID: 14518107
    [No Abstract]   [Full Text] [Related]  

  • 14. Albendazole for lymphatic filariasis.
    Addiss D; Critchley J; Ejere H; Garner P; Gelband H; Gamble C;
    Cochrane Database Syst Rev; 2004; (1):CD003753. PubMed ID: 14974034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
    Irvine MA; Stolk WA; Smith ME; Subramanian S; Singh BK; Weil GJ; Michael E; Hollingsworth TD
    Lancet Infect Dis; 2017 Apr; 17(4):451-458. PubMed ID: 28012943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes.
    Bockarie MJ; Alexander ND; Hyun P; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
    Lancet; 1998 Jan; 351(9097):162-8. PubMed ID: 9449870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albendazole for lymphatic filariasis.
    Critchley J; Addiss D; Gamble C; Garner P; Gelband H; Ejere H;
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003753. PubMed ID: 16235339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coverage survey for assessing mass drug administration against lymphatic filariasis in Gulbarga district, Karnataka, India.
    Ranganath BG
    J Vector Borne Dis; 2010 Mar; 47(1):61-4. PubMed ID: 20231778
    [No Abstract]   [Full Text] [Related]  

  • 19. The development of albendazole for lymphatic filariasis.
    Horton J
    Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S33-40. PubMed ID: 19843396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
    Jambulingam P; Subramanian S; de Vlas SJ; Vinubala C; Stolk WA
    Parasit Vectors; 2016 Sep; 9(1):501. PubMed ID: 27624157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.